Targeted drugs for acute myeloid leukemia include FLT3 inhibitor Gilteritinib, IDH1 inhibitor Evonib, BCL-2 inhibitor Venetoclax and so on. 1. Gilteritinib (Gilteritinib): It is a FLT3 inhibitor, capable of inhibiting FLT3-ITD and FLT3-TKD mutations that are common in acute myeloid leukemia, and approved in January 2021 for the treatment of relapsed or refractory acute myeloid leukemia in adults who carry FLT3 mutations. 2. Ivosidenib: an IDH1 inhibitor that inhibits IDH1 mutations in acute myeloid leukemia, approved in February 2022 for the treatment of adult patients with relapsed or refractory acute myeloid leukemia harboring IDH1 susceptibility mutations. 3. Venetoclax: it is a BCL-2 inhibitor, which can inhibit Bcl-2 protein and restore apoptosis mechanism of tumor cells, thus controlling the disease. It was approved in December 2020 for the treatment of adult patients with primary acute myeloid leukemia who are 75 years old and above or who are unsuitable for strong induction chemotherapy due to comorbidities, in combination with azacitidine or decitabine or low-dose cytarabine. There may be side effects associated with the treatment of the above drugs, for example, giritinib may have side effects such as muscle pain and fatigue, evonib may have side effects such as nausea and cardiac discomfort, and venetoclax may have side effects such as lowered white blood cells and diarrhea, and is contraindicated in people who are allergic to the drugs. Before treatment need to test the relevant gene mutation situation, so it is recommended that patients must be applied under the guidance of the doctor, not self-use.